Alzheimer’s Disease, Amyloid, and Antibodies: Experts Grapple with Evolving Definitions and Treatment Dilemmas
The landscape of Alzheimer’s disease diagnosis and treatment is undergoing a profound transformation, driven by advancements in understanding the disease’s underlying biology and the development of novel therapeutic agents. This evolution presents significant challenges and opportunities for clinicians, researchers, and patients alike. In a recent discussion hosted by the GeriPal Podcast, leading experts convened to explore the complexities surrounding the definition of Alzheimer’s disease, the role of biomarkers, and the clinical implications of emerging antibody-based therapies.
The conversation featured a distinguished panel: Dr. Heather Whitson, a geriatrician and researcher at Duke University and co-director of the Duke UNC Alzheimer’s Disease Research Center; Dr. Halima Amjad, a geriatrician, researcher, and dementia specialist at Johns Hopkins; and Dr. Barak Gaster, a primary care clinician and dementia expert at the University of Washington. Their collective expertise spans the spectrum from primary care to highly specialized dementia clinics, providing a comprehensive view of the current state of Alzheimer’s research and clinical practice.
The Shifting Definition of Alzheimer’s Disease
A central theme of the discussion revolved around the evolving definitions of Alzheimer’s disease, particularly the interplay between clinical symptoms and pathological markers. Traditionally, a diagnosis of Alzheimer’s required both clinical evidence of cognitive impairment and pathological confirmation of amyloid plaques and tau tangles in the brain, often determined post-mortem. However, the advent of sensitive biomarkers, including blood tests and PET scans, has introduced the possibility of diagnosing Alzheimer’s disease based on biological evidence, even in the absence of overt cognitive symptoms.
Dr. Gaster highlighted the challenges faced by primary care providers in navigating these evolving definitions. He emphasized the importance of identifying cognitive impairment, whether it be mild cognitive impairment (MCI) or dementia, as the crucial first step. However, he also stressed the need to use the term "Alzheimer’s disease" when appropriate, as it is the language most familiar to patients and their families, even when the precise etiology remains uncertain or mixed.
Dr. Whitson acknowledged the rapid pace of change in the field, noting the lack of complete consensus among experts. She articulated her personal stance, which embraces the concept of "preclinical Alzheimer’s disease," where the presence of amyloid pathology in the brain, even without symptoms, can be considered a diagnosis. This perspective, she explained, is rooted in the potential for early intervention and risk reduction strategies. However, she also recognized the practical challenges this presents, particularly concerning patient understanding and the potential for misinterpretation of diagnostic information, which can lead to undue anxiety.
Dr. Amjad echoed Dr. Whitson’s sentiment regarding the lack of expert agreement, emphasizing that in her clinical practice, she refrains from ordering biomarkers for cognitively unimpaired individuals. She believes that the clinical syndrome of MCI or dementia must be present to warrant such investigations. While acknowledging the research value of identifying preclinical Alzheimer’s, she cautioned against applying this definition broadly in clinical settings due to the potential for patient distress and the current limitations in definitively linking preclinical pathology to future cognitive decline.
The Role and Limitations of Biomarkers
The discussion extensively explored the utility and interpretation of biomarkers in diagnosing and managing Alzheimer’s disease. Blood-based biomarkers, such as p-tau217 and amyloid beta ratios, have emerged as promising tools, offering a less invasive and more accessible alternative to PET scans and cerebrospinal fluid (CSF) analysis.
Dr. Whitson noted that while these biomarkers are valuable, they are not infallible. She highlighted the need for confirmation with more definitive methods like PET scans or lumbar punctures, especially when initial blood tests yield intermediate results. She also emphasized that the performance characteristics of various biomarkers can differ significantly, underscoring the importance of using validated and reliable tests.
Dr. Gaster strongly advised against the use of biomarkers for screening cognitively unimpaired individuals, a sentiment shared by the entire panel. He likened the situation to a "trap" where a biomarker result might be obtained in the absence of a clinical indication, leading to complex and often unnecessary interpretations. He stressed that the primary focus in primary care should remain on identifying cognitive concerns and conducting thorough cognitive evaluations, rather than relying on isolated biomarker results.
The panel also addressed the potential for direct-to-consumer marketing of these tests, a growing concern that raises ethical and clinical questions. Dr. Gaster and Dr. Whitson both decried such practices, citing the potential for harm and the lack of adequate counseling and interpretation that often accompanies these direct-to-consumer offerings.
Navigating the Landscape of Antibody Therapies
The recent approval of amyloid-targeting monoclonal antibodies, such as lecanemab (Leqembi) and donanemab, has opened a new therapeutic avenue for early-stage Alzheimer’s disease. However, these treatments are not without their complexities, including potential side effects like ARIA (amyloid-related imaging abnormalities) and the significant burden of regular infusions and monitoring.
Dr. Whitson described the conversations around these treatments as some of the most challenging she has encountered in her career as a geriatrician. She acknowledged the delicate balance between potential benefits and risks, stating that for her personally, the scales often tip towards not taking such medications unless the benefit clearly outweighs the risk. She pointed out that for many patients, the logistical demands of treatment, including frequent clinic visits and monitoring, can significantly impact their quality of life.
Dr. Amjad echoed this sentiment, noting that while the availability of these treatments is a significant advancement, the decision to pursue them is highly individualized. She emphasized that many patients, even when eligible, opt against treatment due to concerns about side effects or the overall burden of the therapy.
Dr. Gaster highlighted the crucial role of primary care in initiating these conversations. He stressed the importance of primary care providers being aware of the available treatments, their indications, and the general benefits and risks, so they can appropriately guide patients and facilitate referrals to specialists when necessary. However, he also cautioned against primary care providers making definitive recommendations or judgments about treatment eligibility, given the complexity and the need for specialized interpretation of diagnostic information.
Future Directions and Unanswered Questions
The discussion concluded with a forward-looking perspective on the future of Alzheimer’s disease management. The experts acknowledged the ongoing research into primary prevention strategies and the potential impact of treatments that target individuals in the earliest stages of the disease.
Dr. Whitson expressed a keen interest in long-term data from primary prevention trials, suggesting that a drug proven to delay or prevent the onset of MCI and dementia would be a significant advancement. She also noted the potential for subcutaneous formulations of antibody therapies to ease the burden of administration.
The panel agreed that the field is still in its nascent stages, with many unanswered questions regarding the optimal use of biomarkers, the long-term efficacy and safety of emerging treatments, and the most effective ways to communicate complex diagnostic and therapeutic information to patients and their families. The ongoing dialogue and research are critical to navigating this rapidly evolving landscape and ultimately improving the lives of those affected by Alzheimer’s disease. The commitment of clinicians like Dr. Whitson, Dr. Amjad, and Dr. Gaster to fostering understanding and facilitating informed decision-making remains paramount in this endeavor.
